Related Experiment Video

Updated: Sep 28, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk

Jim McKenney1

  • 1National Clinical Research, Richmond, Virginia 23294, USA. jmckenney@ncrinc.net

The American Journal of Cardiology
|December 7, 2002
PubMed

Insights

Lowering LDL cholesterol is crucial for reducing coronary artery disease risk. Combination therapy is more effective than monotherapy for most patients with high LDL cholesterol and CAD.

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Elevated low-density lipoprotein (LDL) cholesterol is a primary risk factor for coronary artery disease (CAD).
  • Achieving target LDL cholesterol levels is essential for effective CAD risk reduction.
  • Monotherapy often proves insufficient for managing hyperlipidemia in patients with CAD.

Purpose of the Study:

  • To review the efficacy and considerations of combination therapy for managing elevated LDL cholesterol.
  • To emphasize the importance of multifaceted treatment strategies in CAD risk reduction.
  • To highlight the role of combination therapy in achieving treatment goals for patients with CAD.

Main Methods:

  • Literature review on combination therapy for LDL cholesterol management.
  • Analysis of studies evaluating the effectiveness of combination therapy versus monotherapy.
  • Discussion of clinical considerations for implementing combination therapy in CAD patients.

Main Results:

  • Combination therapy demonstrates superior efficacy in lowering LDL cholesterol compared to monotherapy.
  • A significant majority of patients with CAD require combination therapy to reach their LDL cholesterol goals.
  • Aggressive CAD risk reduction necessitates a multi-pronged therapeutic approach.

Conclusions:

  • Combination therapy is a cornerstone in the effective management of elevated LDL cholesterol for CAD risk reduction.
  • Individualized treatment plans incorporating combination therapy are vital for optimizing patient outcomes.
  • Further research into optimizing combination therapy regimens is warranted.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...